Head to head
Monopar Therapeutics vs Vertex Pharmaceuticals
Side-by-side on the measures that matter, with a plain-English read. Full detail: MNPR · VRTX
MNPR
Monopar Therapeutics
82.54-1.48%
1-year price shape — -15% over the period
Quant Rating D · 53/100
vs
VRTX
Vertex Pharmaceuticals
506.64+0.20%
1-year price shape — +23% over the period
Quant Rating C · 67/100
1-year performance, rebased to 100
Vertex Pharmaceuticals edges it on the scoreable measures. Vertex Pharmaceuticals has the highest Quant Rating (67); Vertex Pharmaceuticals has done best over the past year (+23%); Vertex Pharmaceuticals earns the most per share.
| MNPR | VRTX | |
|---|---|---|
| Snapshot | ||
| Sector | Biotechnology | Biotechnology |
| Last price | 82.54 | 506.64 |
| Change today | -1.48% | +0.20% |
| 1-year return | -15.0% | +23.2% |
| Market cap | $554.02M | $128.41B |
| 52-week range | 50.07 – 124.82 | 402.58 – 560.25 |
| Valuation | ||
| P/E (TTM) | -37.52 | 29.51 |
| P/E percentile, own 5-yr range | 5th | 74th |
| P/B | 4.23 | 6.34 |
| Dividend yield | 0.00% | 0.00% |
| Profitability & growth | ||
| EPS (TTM) | -1.85 | 15.32 |
| Net profit (TTM) | $-12.42M | $3.88B |
| Revenue (TTM) | $0 | $12.59B |
| Revenue growth (YoY) | -- | +12.5% |
| Gross margin | -- | 86.0% |
| Operating margin | -- | 37.9% |
| Net margin | -- | 35.0% |
| Free cash flow (TTM) | $-12.18M | $3.80B |
| Ownership & sentiment | ||
| Institutional ownership | 109.1% | 97.2% |
| Insider activity (12mo) | 31 buy / 19 sell | 25 buy / 25 sell |
| Short interest (% of float) | 12.6% | 1.9% |
| Analyst consensus | 86% buy / 14% hold (7) | 88% buy / 8% hold / 4% sell (24) |
| Analyst price target | $129 (+57%) | $580 (+15%) |
| StockVane view | ||
| StockVane Quant Rating | D (53) | C (67) |
| Company | ||
| Employees | 22 | 6,400 |
| Founded | 2014 | 1989 |
▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.